molecules of the month

“compound 3d”

sphingosine-1-phosphate recep. mod. prodrug

for multiple sclerosis, proj. human t1/2 of 5d

from opt. of prior S1P1 modulators

ACS Med. Chem. Lett., Aug. 11, 2020

Bristol-Myers Squibb, Princeton, NJ

Chemical structure of the "compound 3d" prodrug
1 min read

“compound 3d” is a prodrug which is phosphorylated in vivo to form a potent sphingosine-1-phopshate receptor modulator. BMS took two previous compounds into the clinic for MS with the goal of differentiating from fingolimod on safety. One potential issue for a previous compound was an overly long (12 day) half-life which could be undesirable in certain settings such as those involving drug-drug interactions. Therefore “compound 3d” was developed to have a shorter preducted human half-life of “only” 5 days.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: